RxSight (RXST) Scheduled to Post Earnings on Thursday

RxSight (NASDAQ:RXST - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.02 per share for the quarter. Investors interested in registering for the company's conference call can do so using this link.

RxSight (NASDAQ:RXST - Get Free Report) last announced its earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.06. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The company had revenue of $34.89 million for the quarter, compared to analyst estimates of $32.33 million. During the same period in the previous year, the firm earned ($0.40) earnings per share. RxSight's revenue for the quarter was up 67.6% compared to the same quarter last year. On average, analysts expect RxSight to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RxSight Stock Performance

Shares of NASDAQ:RXST traded down $1.08 during midday trading on Thursday, reaching $50.13. The company had a trading volume of 102,155 shares, compared to its average volume of 465,918. The company has a fifty day simple moving average of $51.83 and a two-hundred day simple moving average of $53.63. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of -50.21 and a beta of 1.20. RxSight has a 1-year low of $21.14 and a 1-year high of $66.54.

Insider Buying and Selling at RxSight

In related news, insider Ilya Goldshleger sold 3,100 shares of the business's stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $53.19, for a total transaction of $164,889.00. Following the completion of the sale, the insider now directly owns 42,246 shares of the company's stock, valued at $2,247,064.74. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last three months, insiders have sold 49,310 shares of company stock worth $2,370,917. Company insiders own 9.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on RXST shares. Needham & Company LLC reissued a "buy" rating and issued a $66.00 price target on shares of RxSight in a research report on Friday, September 13th. Stifel Nicolaus decreased their target price on RxSight from $70.00 to $65.00 and set a "buy" rating for the company in a research note on Tuesday, August 6th. Oppenheimer decreased their price target on shares of RxSight from $72.00 to $65.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 6th. BTIG Research increased their price target on shares of RxSight from $72.00 to $73.00 and gave the stock a "buy" rating in a research report on Monday, July 15th. Finally, Wells Fargo & Company lowered their price target on RxSight from $68.00 to $54.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 6th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $61.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.